EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment

Seo Jeong Kim, Ji Seob Kim, Min Hee Moon, Jae-Hyeok Jang, In Sun Hwang, Byung-Hyun Cha iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.71406 ↗

At a glance

Journal article in Advanced Healthcare Materials, 2026. Written by Seo Jeong Kim and 5 co-authors. Institution: Department of Biomedical Systems Science, College of Biomedical Science, Kangwon National University, Chuncheon-si, Republic of Korea. Major MEDLINE topics: Extracellular Vesicles, Mesenchymal Stem Cells, Osteoarthritis, Fibroblasts. Cited 1 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Research Foundation of Korea, Korea government, Ministry of Health & Welfare, Republic of Korea.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Mesenchymal stem cells (MSCs) migrate to injured tissues through a homing effect and promote tissue regeneration by secreting paracrine factors and extracellular vesicles (EVs) and interacting with resident cells. MSC‐derived EVs have emerged as promising therapeutic candidates for osteoarthritis (OA) because they carry bioactive molecules, are easily delivered, and exhibit low immunogenicity. In this study, we generated MSCs with altered cell fate by transferring the microenvironment of SW982 human synovial fibroblast‐like cells through direct MSC–synovial fibroblast (SF) interaction and evaluated EVs derived from these cells (miSF‐MSC‐EVs) as a therapeutic strategy for OA. MSCs and SFs were stained with nuclear dyes, co‐cultured for 48 h, and double‐positive cells were isolated by fluorescence‐activated cell sorting. Proteomic and next‐generation sequencing analyses revealed enrichment of miRNAs associated with cell migration, adhesion, and transforming growth factor‐β, Wnt, and PI3K signaling pathways in miSF‐MSC‐EVs. Compared with conventional MSC‐EVs, miSF‐MSC‐EVs enhanced cell proliferation, improved regenerative responses, reduced inflammatory marker expression, and increased anti‐inflammatory marker expression in vitro. Furthermore, miSF‐MSC‐EVs promoted cartilage repair in a mouse OA model, highlighting their potential as a regenerative therapeutic platform for OA treatment.

Subjects

MeSH terms (MEDLINE)

Extracellular VesiclesMesenchymal Stem CellsOsteoarthritisFibroblastsSynovial MembraneHumansAnimalsMiceCell ProliferationCell MovementMicroRNAs

Author keywords

cell to cell interactionextracellular vesicles (EVs)mesenchymal stem cells (MSCs)osteoarthritis (OA)synovial fibroblasts

Substances

MicroRNAs

Authors and institutions

  • Department of Biomedical Systems Science, College of Biomedical Science, Kangwon National University, Chuncheon-si, Republic of Korea.

ORCID profiles: Byung-Hyun Cha

Funding

  • National Research Foundation of Korea
  • Korea government
  • Ministry of Health & Welfare, Republic of Korea

Cite

APA

Kim, S. J., Kim, J. S., Moon, M. H., Jang, J. H., Hwang, I. S., & Cha, B. H. (2026). Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71406

Vancouver

Kim SJ, Kim JS, Moon MH, Jang JH, Hwang IS, Cha BH. Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71406

BibTeX
@article{Kim2026,
  author = {Kim, Seo Jeong and Kim, Ji Seob and Moon, Min Hee and Jang, Jae-Hyeok and Hwang, In Sun and Cha, Byung-Hyun},
  title = {Therapeutic Extracellular Vesicles from Synovial Fibroblast‐Primed MSCs for Osteoarthritis Treatment},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71406}
}
Start for free →